-
公开(公告)号：US08143243B2
公开(公告)日：2012-03-27
申请号：US12369222
申请日：2009-02-11
IPC分类号： A61P31/00 , A61K31/55 , C07D223/14
CPC分类号： C07D487/04 , C07D401/14 , C07D403/04 , C07D409/04 , C07D413/04 , C07D413/14
摘要： The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
摘要翻译： 本发明包括式I化合物以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。
-
公开(公告)号：US20090042860A1
公开(公告)日：2009-02-12
申请号：US12184791
申请日：2008-08-01
申请人： Carl P. Bergstrom , Scott W. Martin
发明人： Carl P. Bergstrom , Scott W. Martin
IPC分类号： A61K31/55 , C07D223/32 , A61P31/00
CPC分类号： C07D487/04 , C07D519/00
摘要： The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
摘要翻译： 本发明包括式I的化合物以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。
-
公开(公告)号：US07642251B2
公开(公告)日：2010-01-05
申请号：US12184791
申请日：2008-08-01
申请人： Carl P. Bergstrom , Scott W. Martin
发明人： Carl P. Bergstrom , Scott W. Martin
IPC分类号： A61P31/00 , A61K31/55 , C07D223/14
CPC分类号： C07D487/04 , C07D519/00
摘要： The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
-
公开(公告)号：US07456165B2
公开(公告)日：2008-11-25
申请号：US11671753
申请日：2007-02-06
IPC分类号： A61K31/55 , A61P31/00 , C07D223/14
CPC分类号： C07D487/04
摘要： The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
摘要翻译： 本发明包括式I化合物以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。
-
公开(公告)号：US20070185083A1
公开(公告)日：2007-08-09
申请号：US11671753
申请日：2007-02-06
IPC分类号： A61K31/55 , C07D487/04
CPC分类号： C07D487/04
摘要： The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
摘要翻译： 本发明包括式I化合物以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。
-
16.发明授权
公开(公告)号：US5421699A
公开(公告)日：1995-06-06
申请号：US276683
申请日：1994-07-18
CPC分类号： B65H31/3027 , B65H39/02 , B65H2301/33 , B65H2301/42262 , B65H2404/1112
摘要： Apparatus and a method for merging vertically oriented documents with horizontally oriented documents. The apparatus includes: a document assembler for receiving vertically oriented documents, the document assembler having a pair of parallel paper paths, wherein each of the paper paths includes a device for transporting the vertically oriented documents and a device for stopping and a device for aligning the vertically oriented documents; a device located beneath the document assembler for re-orienting the documents from the document assembler in a vertical orientation to a horizontal orientation; and a horizontal transport located beneath the re-orienting device for feeding horizontally oriented documents toward the re-oriented documents emerging from the re-orienting device, whereby the horizontally oriented documents are merged with the re-oriented documents from the document assembler.
摘要翻译： 用于将垂直定向文档与水平定向的文档合并的装置和方法。 该装置包括：用于接收垂直取向的文件的文档汇编器，该文档汇编器具有一对平行纸路径，其中每个纸路径包括用于传送垂直取向的文件的装置和用于停止的装置，以及用于对准 垂直文件; 位于文档汇编器下方的装置，用于将文档从文档汇编器以垂直取向重新定向到水平方向; 以及位于重新定向装置下面的水平传送器，用于将水平定向的文件朝向从重新定向装置出现的重新定向的文件供给，由此水平定向的文档与来自文档组装器的重新定向的文档合并。
-
公开(公告)号：US07183302B2
公开(公告)日：2007-02-27
申请号：US10637099
申请日：2003-08-08
申请人： Jeffrey Lee Romine , Scott W. Martin , Lawrence B. Snyder , Michael Serrano-Wu , Milind Deshpande , Darren Whitehouse , Julie Lemm , Donald O'Boyle , Min Gao , Richard Colonno
发明人： Jeffrey Lee Romine , Scott W. Martin , Lawrence B. Snyder , Michael Serrano-Wu , Milind Deshpande , Darren Whitehouse , Julie Lemm , Donald O'Boyle , Min Gao , Richard Colonno
IPC分类号： A61K43/78 , C07D277/18
CPC分类号： C07D417/04 , A61K31/00 , A61K31/426 , A61K38/2013 , A61K38/204 , A61K38/208 , A61K38/21 , A61K38/212 , A61K45/06 , C07D277/42 , C07D417/06 , C07D417/12 , C07D417/14 , C07D513/04 , A61K2300/00
摘要： Compounds having the structure of formula I are described wherein R, R′, R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.
摘要翻译： 描述了具有式I结构的化合物，其中R 1，R 2，R 1，R 2和R 3均如 规范。 该化合物可以抑制丙型肝炎病毒（HCV）复制，特别是HCV NS5A蛋白的功能。
-
公开(公告)号：US06271249B1
公开(公告)日：2001-08-07
申请号：US09538520
申请日：2000-03-29
申请人： Jeffrey L. Romine , Scott W. Martin , Piyasena Hewawasam , Nicholas A. Meanwell , Valentin K. Gribkoff , John E. Starrett, Jr.
发明人： Jeffrey L. Romine , Scott W. Martin , Piyasena Hewawasam , Nicholas A. Meanwell , Valentin K. Gribkoff , John E. Starrett, Jr.
IPC分类号： A61K31402
CPC分类号： C07D263/58 , C07D233/64 , C07D233/70 , C07D233/76 , C07D235/12 , C07D249/12 , C07D249/14 , C07D271/113 , C07D413/10
摘要： Novel compounds of Formula 1 are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels: wherein “Het” is one of a select group of heterocyclic moieties; Z is independently for each occurrence selected from O or S; Ra, Rb and Rc each are independently selected from hydrogen, halogen, OH, CF3, NO2, or provided Rc is not hydrogen; and when Ra and Rb are hydrogen, Rc may be a heterocyclic moiety selected from the group consisting of imidazol-1-yl, morpholinomethyl, N-methylimidazol-2-yl, and pyridin-2-yl; Rd and Re each are independently selected from hydrogen, halogen, CF3, NO2 or imidazol-1-yl; m, n and p each are independently selected from an integer of 0 or 1; and Rf and Rg each are independently hydrogen; C1-4 alkyl; or Rf and Rg, taken together with the nitrogen atom to which they are attached, is a heterocyclic moiety selected from the group consisting of N-methylpiperazine, morpholine, thiomorpholine, N-benzylpiperazine and imidazolinone.
摘要翻译： 式1的新型化合物可用于治疗对大电导钙激活钾通道的开放剂起反应的病症：其中“Het”是选择性杂环部分组之一; Z独立地选自O或S; R a，R b和R c各自独立地选自氢，卤素，OH，CF 3，NO 2，或提供的R c不是氢; 当R a和R b为氢时，R c可以是选自咪唑-1-基，吗啉代甲基，N-甲基咪唑-2-基和吡啶-2-基的杂环部分; Rd和Re各自独立地选自氢，卤素，CF 3，NO 2或咪唑-1-基; m，n和p各自独立地选自0或1的整数; Rf和Rg各自独立地为氢; C 1-4烷基 或R f和R g与它们所连接的氮原子一起是选自N-甲基哌嗪，吗啉，硫代吗啉，N-苄基哌嗪和咪唑啉酮的杂环部分。
-
19.发明授权公开(公告)号：US10291417B2
公开(公告)日：2019-05-14
申请号：US11959680
申请日：2007-12-19
摘要： A method and system for providing distributed network access point installation and management. A network provider installs and/or operates a plurality of access points at locations of a retail entity. Each access point may provide services such as Internet access, and/or content such as audio, video, text, and/or graphics, among other types of services. A carrier, such as a telephone or cable company, may compensate the network service provider for installation and operation of the access points. The carrier may in turn charge its subscribers for network access at the retail entity locations. A plurality of different carriers may provide compensation and allow respective subscriber access. The network access points may be configured to allow each carrier to present a point of presence to its subscribers at the retail entity locations. The installed network may also provide service for retail entity back office functions.
-
公开(公告)号：US07112601B2
公开(公告)日：2006-09-26
申请号：US10922096
申请日：2004-08-19
IPC分类号： A61K31/415 , C07D231/12 , C07D231/14 , C07D231/16
CPC分类号： C07D231/12 , C07D231/14
摘要： Compounds of Formula I are disclosed which inhibit hepatitis C NS5B RNA-dependent RNA polymerase and are useful for treating hepatitis C. Compositions and methods of using these compounds are also disclosed
摘要翻译： 公开了抑制丙型肝炎NS5B RNA依赖性RNA聚合酶并可用于治疗丙型肝炎的式I化合物。也公开了使用这些化合物的组合物和方法
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.041 秒)
